Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BRCA (Breast cancer early onset)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FoundationOne® Liquid CDx (20)

PredicineCARE™

FoundationOne® Liquid CDx (20)

PredicineCARE™

›

HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2	bevacizumab + olaparib Sensitive: A2 - Guideline bevacizumab + olaparib Sensitive : A2
HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
BRCA mutation	HER2 Negative Breast Cancer	BRCA mutation	HER2 Negative Breast Cancer	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B
BRCA wild-type + TP53 mutation	Ovarian Cancer	BRCA wild-type + TP53 mutation	Ovarian Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3	D19466 Sensitive: C3 – Early Trials D19466 Sensitive : C3
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	carboplatin Sensitive: C3 – Early Trials carboplatin Sensitive : C3	carboplatin Sensitive: C3 – Early Trials carboplatin Sensitive : C3
HRD + BRCA wild-type	Triple Negative Breast Cancer	HRD + BRCA wild-type	Triple Negative Breast Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3
HR positive + BRCA positive	HER2 Positive Breast Cancer	HR positive + BRCA positive	HER2 Positive Breast Cancer	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4
BRCA mutation	Pancreatic Ductal Adenocarcinoma	BRCA mutation	Pancreatic Ductal Adenocarcinoma	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D
BRCA mutation	Diffuse Large B Cell Lymphoma	BRCA mutation	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D
BRCA deletion	Ovarian Cancer	BRCA deletion	Ovarian Cancer	olaparib + AZD7648 Sensitive: D – Preclinical olaparib + AZD7648 Sensitive : D	olaparib + AZD7648 Sensitive: D – Preclinical olaparib + AZD7648 Sensitive : D
BRCA wild-type + TP53 mutation	Lung Cancer	BRCA wild-type + TP53 mutation	Lung Cancer	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D
BRCA wild-type + TP53 mutation	Breast Cancer	BRCA wild-type + TP53 mutation	Breast Cancer	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D
TP53 R280K + BRCA wild-type	Triple Negative Breast Cancer	TP53 R280K + BRCA wild-type	Triple Negative Breast Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D